New post hoc analysis confirms: Airsonett TLA effective for severe asthma exacerbations, improves quality of life and is cost-effective
The Swedish MedTech company Airsonett’s treatment for severe allergic diseases, TLA, has been proven effective for patients with severe exacerbations (asthma flare-ups) and improving the quality of life while being cost-effective. That is the result of a new post hoc analysis of a previous study. TLA treatment creates a zone of 99.5 percent clean air...
Read More...
Fåhraeus Startup & Growth invests in the Swedish Medtech company Airsonett – Christer Fåhraeus to join the board
Fåhraeus Startup & Growth Fund joins as an owner of the Swedish Medtech company Airsonett, which is facing an international expansion. Airsonett has developed the patented method TLA, for effective treatment of severe allergic diseases, such as asthma and atopic eczema, with clean air. The treatment has been used for a few years in Swedish...
Read More...
New observational study shows significant effect of Airsonett TLA treatment on adult atopic dermatitis patients
Airsonett announced today a new observational study showing a significant effect of Airsonett TLA (Temperature-controlled Laminar Airflow) for treating adult atopic dermatitis (AD) patients. The proof-of-concept study is published in the Journal of the European Academy of Dermatology and Venereology. Atopic dermatitis patients are commonly sensitized to house dust mites. The current consensus-based European guideline...
Read More...
Airsonett expands into Italy by signing distributor contract with INNOVACAREMD
Airsonett announced today that the company is expanding into the Italian market through a distributor partnership with INNOVACAREMD. The company will distribute Airsonett’s unique medical device for TLA treatment (Temperature-controlled Laminar Airflow), the patented and effective treatment of allergic diseases such as allergic asthma and atopic eczema. The partnership is the next step forward in...
Read More...
Poster by Paul Miller: “The Cost-effectiveness of Temperature-controlled Laminar Airflow in uncontrolled severe asthma”
Paul Miller presented a poster at the Swedish Lung Congress. You can see the presentation on their webpage, and you can also download the poster as pdf The Cost-effectiveness of Temperature-controlled Laminar Airflow in uncontrolled severe asthma Paul Miller1, Leif Bjermer2, Stefan Petersson3, Göran Eriksson2, Anoop Chauhan4, 1Miller Economics Ltd, BIOHUB Alderley Park, Alderley Edge,...
Read More...
New publication with TLA confirms a significant reduction of severe exacerbations and increased Quality of Life for patients with severe allergic asthma
Airsonett announced today a new publication: “Effect of nocturnal Temperature-controlled Lami-nar Airflow on the reduction of severe exacerbations in patients with severe allergic asthma: a meta-analysis”1 The study concludes that nocturnal use of TLA (Temperature-controlled Laminar Airflow) shows a beneficial effect on severe exacerbations and quality of life in more symptomatic patients with severe allergic...
Read More...
New study evaluates Airsonett TLA technology in the treatment of children with severe atopic eczema
Airsonett announced today that the company’s novel and proprietary technology TLA (Temperature-controlled Laminar Airflow) would be evaluated in the treatment of children with severe atopic eczema. Imperial College London UK will perform and sponsor the single centre, randomized placebo-controlled study. The study is a result of the positive results already seen in the proof of...
Read More...
Information for our clients and patients with severe, uncontrolled allergic asthma in regards to the Corona virus
Airsonett have received queries about how we, as a company, work to minimise the spreading of the Corona virus and how we secure delivery of new Airsonett devices and filters to our clients and patients. We daily monitor the guidelines and directives from the UK Authorities and try to plan and act in a responsible...
Read More...
New agreement for Airsonett with the region of Halland in Sweden for treatment of severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with TLA via public healthcare
Airsonett AB announced today that the company had signed an agreement with the region of Halland in Sweden. The agreement is for the treatment of patients with severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with the company’s patented technology Temperature-controlled Laminar Airflow (TLA). The technology gives patients particle- and allergen-free air when they rest...
Read More...
Airsonett signs agreement with the region of Kalmar in Sweden for treatment of severe allergic asthma with TLA via public healthcare
Airsonett announced today that the company has signed an agreement with the region of Kalmar for the treatment of patients with severe allergic asthma. The agreement is the third of its kind for Airsonett in Sweden this year, for prescription of the company’s unique treatment; Temperature controlled Laminar Airflow (TLA). The technology treats severe allergic...
Read More...
Patient survey: 97% have a better quality of life with Airsonett
This year we have conducted an examination among users of Airsonett Air4 in Sweden with allergic asthma, and we are quite proud of the answers. A majority of the users answered, of which 97% (!) state that they have a better quality of life with the treatment. A majority of the users say that have...
Read More...
Airsonett signs a new agreement: patients with severe allergic asthma in Region Västra Götaland can now receive treatment with TLA via public healthcare
Region Västra Götaland is the latest in a line of Swedish regions to sign an agreement with Air-sonett for TLA treatment. The regions Stockholm and Östergötland have previously signed similar agreements. The agreement is for prescription of the company’s unique treatment, Temperature controlled Laminar Airflow (TLA), that treats severe allergic asthma patients with particle-free air....
Read More...
The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma
The expert group for respiratory organs in the region of Östergötland has since 2016 recommended TLA as a complementary treatment for adults and children over 6 with severe asthma, who, despite optimal medication, have uncontrolled asthma. However, the prescription was previously limited to the allergy center in Linköping. With the new central agreement, it is...
Read More...
Airsonett supports the Allergy Diary App – assists in the care of allergic asthma
The new app Allergy Diary has been developed for IOS and Android in collaboration between MACVIA-LR and ARIAR, a European network for monitoring allergy. The app is an important tool for the effective treatment of severe allergic asthma as it assists patients in keeping track of their symptoms. The app is simple to use, and...
Read More...
Airsonett’s TLA technology is now included in the guidelines for treatment of severe asthma in the South Swedish national health care
National health care in the South Swedish region of Skåne has updated its guidelines for treatment of patients with severe allergic asthma. Airsonett and the treatment with the TLA technology (Temperature-controlled Laminar Airflow)has been given its own guidelines based on the primary indication to prevent asthma attacks (exacerbations). The guidelines have been established by the...
Read More...
Airsonett Air4 provides a clinical improvement in Quality of Life within 3 months of treatment
An independent time to onset (TTO) study, using the Airsonett Air4 Temperature-controlled Laminar Airflow technology (TLA), by Professor Leif Bjermer (Department of Respiratory and Allergology, University Hospital Lund, Sweden), concludes that Nocturnal treatment with TLA provided a statistically significant and clinically relevant improvement in total Quality of Life score (AQLQ) within 3 months in patients...
Read More...
Airsonett AIR4 maintains good control of severe allergic asthma after withdrawal of omalizumab
An independent study by Professor C. Wang concludes in the title of the study “A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma(SAA) after withdrawal of Omalizumab therapy”. The study will be published in a poster session at ERS on Asthma Management session on Sunday 16 September 2018. “We...
Read More...
Airsonett AB announces that the company has appointed Anders Due-Boje as its new CEO
Airsonett AB is a medical device company with a unique technology developed to treat patients with severe asthma. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR-4 is a clinically validated, non-pharmaceutical treatment of asthma, which reduces allergens and other...
Read More...
Airsonett recently signed agreement with distributor in Germany
“Germany is one of our key markets so we are pleased to have signed a distribution agreement with the medical device company OxyCare GmbH. The company is dedicated to promote and launch Airsonett AIR4 on the German market. OxyCare will not only market AIR4 but also handling all logistics,installations and training for the German market....
Read More...
New eczema study with Airsonett AIR4 published
Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London has recently been published. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett AIR4) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with accompanying reduction in medication usage. Allergic...
Read More...
Treatment with Airsonett AIR4 has sustained benefit in children and adolescents with severe allergic eczema (atopic dermatitis)
Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London, was presented Tuesday afternoon at the ongoing EAACI congress in Helsinki. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with...
Read More...
Airsonett AIR4 can generate significant cost savings while still maintaining asthma-related quality of life according to an independent expert review
An independent expert review authored by John O Warner, Professor of Paediatrics, Imperial College London, was today published on-line in Therapeutic Advances in Respiratory Disease. The review concludes that temperature-controlled laminar airflow (TLA) treatment (Airsonett AIR4) improves asthma-related quality of life, reduces airway inflammation and the frequency of severe asthma exacerbations in patients with severe...
Read More...
Airsonett increases its focus on global commercial expansion
Airsonett AB is expanding its International Sales Organization to increase the rate of its commercial expansion by recruiting a new VP Sales and Marketing and appointing a VP Distributor Sales and Business Development. Recently a number of independent expert groups, both in Sweden and the UK, have published positive evaluations of the company’s innovative home...
Read More...
Professor Karl-Christian Bergmann, Charité – Berlin, presented Airsonett data at Allergo 2016 in Cologne
At Allergo-Update’s annual meeting in Cologne, Prof Karl-Christian Bergmann, Charité – Universitätsmedizin, Berlin, presented the latest Airsonett data as part of his speech on Aerobiology. Professor Bergmann pointed out that according to a recent publications, Airsonett treatment (TLA) decreases the number of emergency emissions and exacerbations for patients with severe allergic asthma. Moreover, for patients...
Read More...
Airsonett AIR4 a cost-effective, drug-free alternative for patients with severe allergic asthma
An economic analysis, published today in published in BMJ Open Respiratory Research finds Airsonett AIR4 to be a cost-effective addition to treatment options in patients with uncontrolled severe allergic asthma. For high-risk individuals with more severe and less well controlled asthma the use of Airsonett AIR4 to reduce incidence of hospitalisation would be a cost...
Read More...
